The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.

These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits ...

Yes, weight-loss drugs can help you lose weight – but they can also boost your health in unexpected ways. Good Housekeeping’s ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Anne-Marie Zanzal, 60, and her wife Tonda McKay, 62, have also experienced the more positive changes that weight-loss drugs ...

SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...